This study, through the analysis of several database data, for the first time provides comprehensive evidence that STOX1 is downregulated in high-grade gliomas, correlates with glioma grade, and might serve as an independent prognostic biomarker for glioma patients. This evidence concerns the gene STOX1 and central nervous system cancer.